抗CD19 CAR T细胞巩固治疗联合CD19+饲养T细胞及酪氨酸激酶抑制剂治疗费城染色体阳性急性淋巴细胞白血病
单臂、开放标签、单中心1期研究评估多周期序贯抗CD19 CAR T细胞联合自体CD19+饲养T细胞及酪氨酸激酶抑制剂作为巩固治疗,用于65岁以下初诊费城染色体阳性CD19+ B细胞急性淋巴细胞白血病患者的安全性和疗效。前15例患者(含2例退出)中,13例可评估患者均达完全缓解,其中12例达完全分子学缓解;中位随访27个月,无复发生存率84%,总生存率83%。
要点
- 常见不良事件为血细胞减少(13/13)和低丙种球蛋白血症(12/13)。
- 未发生2级以上细胞因子释放综合征、免疫效应细胞相关神经毒性综合征或4级非血液学毒性。
- 13例患者均达完全缓解,12例达完全分子学缓解;中位随访27个月无复发生存率84%、总生存率83%。
核心结论
- 这些发现可能为开发无需异基因造血干细胞移植的巩固治疗范式奠定基础。
研究设计与样本
- 单臂、开放标签、单中心1期研究,纳入65岁以下初诊费城染色体阳性CD19+ B细胞急性淋巴细胞白血病患者。
- 患者接受诱导化疗及联合酪氨酸激酶抑制剂的全身化疗,随后接受1个周期CD19 CAR T细胞输注及另外3个周期CD19 CAR T细胞和CD19+饲养T细胞输注,之后以酪氨酸激酶抑制剂作为巩固治疗。
- CD19+饲养T细胞给予3种不同剂量;报告前15例患者(含2例退出)的1期结果。
- 试验注册号为NCT03984968。
主要发现
- 最常见不良事件为血细胞减少(13/13)和低丙种球蛋白血症(12/13)。
- 未发生2级以上细胞因子释放综合征、免疫效应细胞相关神经毒性综合征或4级非血液学毒性。
- 13例患者均达完全缓解,其中12例在数据截止时达完全分子学缓解。
- 中位随访27个月,无复发生存率为84%,总生存率为83%。
- 表达CD19的细胞总数随完全分子学缓解率升高而下降;CD19 CAR T细胞存活长达40个月,而CD19+饲养T细胞在末次输注后3个月于8例患者中消失。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We conducted a single-arm, open-label, single-center phase 1 study to assess the safety and efficacy of multicycle-sequential anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in combination with autologous CD19+ feeding T cells (FTCs) and tyrosine kinase inhibitor (TKI) as consolidation therapy in patients under the age of 65 years with de novo Ph-positive CD19+ B-cell acute lymphoblastic leukemia. Participants were given induction chemotherapy as well as systemic chemotherapy with TKI. Afterward, they received a single cycle of CD19 CAR T-cell infusion and another 3 cycles of CD19 CAR T-cell and CD19+ FTC infusions, followed by TKI as consolidation therapy. CD19+ FTCs were given at 3 different doses. The phase 1 results of the first 15 patients, including 2 withdrawals, are presented. The most common adverse events were cytopenia (13/13) and hypogammaglobinemia (12/13). There was no incidence of cytokine release syndrome above grade 2 or immune effector cell-associated neurotoxicity syndrome or grade 4 nonhematological toxicities. All 13 patients achieved complete remission, including 12 patients with a complete molecular response (CMR) at the data cutoff. The relapse-free survival was 84%, and the overall survival was 83% with a median follow-up of 27 months. The total number of CD19-expressing cells decreased with an increasing CMR rate. CD19 CAR T cells survived for up to 40 months, whereas CD19+ FTCs vanished in 8 patients 3 months after the last infusion. These findings could form the basis for the development of an allo-HSCT-free consolidation paradigm. This trial was registered at www.clinicaltrials.gov as #NCT03984968.
引用
- Chen LY, Gong WJ, Li MH, et al. Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia. Blood Adv. 2023. PMID: 36897251. doi:10.1182/bloodadvances.2022009072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。